For U.S. Healthcare Professionals Only

For Healthcare Professionals


References

  1. Freedberg IM, Eisen AZ, Wolff K, et al. Epithelial precancerous lesions. In: Fitzpatrick's Dermatology in General Medicine. New York, NY: McGraw-Hill Publishing, 2003:723.

  2. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70:335-339.

  3. Carac® Prescribing Information. Dermik Laboratories, 2006.

  4. Loven K, Stein L, Furst K, Levy S. Evolution of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990-1000.

  5. Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther. 2001;23:901-907.

  6. Won R, inventor; Advanced Polymer Systems Inc, assignee. Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen. US patent 4,690,825. September 1,1987.

  7. Won R, Katz MA, Cheng CH, Nacht S, inventors; Advanced Polymer Systems Inc, assignee. Methods and compositions for topical delivery of retinoic acid. US patent 5,955,109. September 21,1999.

  8. A.P. Pharma. Topical technology. Available at: http://www.appharma.com/PDFs/topicalsht.pdf. Accessed February 26, 2007.

  9. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70:22-29.

Microsponge® is a registered trademark of Cardinal Health, Inc., its successors and assigns.

[Image of grass][Image of grass]
Carac® is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.
IMPORTANT SAFETY INFORMATION
Carac® is contraindicated in women who are or may become pregnant, in patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency, and in patients with known hypersensitivity to any of its components. In clinical trials, the most common drug-related adverse event was application site reaction (94.6%), which included: erythema, dryness, burning, erosion, pain, and edema. Some patients also experienced eye irritation (5.4%), including stinging and burning.
For more information, please see Full Prescribing Information for Carac®.